MicroRNA-186 suppresses cell proliferation and metastasis in bladder cancer.

Purpose: Bladder cancer (BCa) is a common malignancy in the urinary system. This study aims to explore the role of miR-186 in BCa tumorigenesis.

Methods: The expression of miR-186 and ADAMTS12 in clinical BCa tissues and cell lines was detected.

Bacterial Community Selection of Mycosphere Soil.

is a wild, ectomycorrhizal, edible, and medicinal fungus with high economic value in southern China. fruiting bodies cannot be artificially cultivated. To better understand the effects of abiotic and biotic factors on growth, the physicochemical properties of and its associated bacterial communities were investigated in two soil types (mycosphere and bulk soil) from Fujian, Guangdong, and Guangxi Provinces.

Fungal Systematics and Evolution: FUSE 5.

Thirteen new species are formally described: from Pakistan, from India, on from Iran, from China, on species of , , and (Coleoptera, Carabidae) from Nicaragua and Panama, on (Hemiptera, Veliidae) from Brazil, on (Blattodea, Termitidae) from the DR Congo, from Slovenia, from Peru, from China, on from Italy, from , on subsp. from Pakistan. The following new records are reported: on from India; on apple and quince fruits from Iran; from Turkey; and on from Italy; causing tip blight of '' from India; from Madeira, Portugal, new for Macaronesia and Africa; , , and from Russia; on from India; on from Italy; on from Austria; from Turkey; from Wisconsin, USA; and from Turkey.

Adhesive Gold Nanoparticles for Easy and Controlled Surface Coating.

Gold nanoparticles (Au NPs) are one of the most important nanomaterials due to their unique properties and broad applications. Among these applications, decorating Au NPs on universal surfaces is highly desired. Herein, we report adhesive Au NPs functionalized by borated dopamine dithiocarbamate.

The ATTEMPTS delivery systems for macromolecular drugs.

Aiming at successful targeted drug delivery - a system that possesses both targeting and prodrug features that can be activated once the system reaches the target site upon systemic administration - would be desired to reduce systemic toxicity. Previously we proposed a heparin/protamine-based system for delivery of protease drugs such as tissue-specific plasminogen activator (t-PA). This approach, termed 'antibody targeted, triggered, electrically modified prodrug-type strategy' (ATTEMPTS), would permit antibody-directed administration of inactive t-PA and allow a subsequent triggered release of the active t-PA at the target site.

The minimal functional sequence of protamine.

Despite its nearly universal applications, protamine, a mixture of four major peptides with different sequences, is associated with clinically significant side effects. Through a well-designed enzyme digestion method, various low molecular weight protamine peptides were obtained. Among them, two low molecular weight protamine peptides with the same or even more potent heparin neutralization abilities as native protamine were identified through both in vitro and in vivo tests.

Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study.

Naturally derived, nontoxic peptides from protamine by the authors, termed low molecular weight protamines (LMWPs), possess high arginine content and carry significant sequence similarity to that of TAT, by far the most potent protein transduction domain peptide. Therefore, it was hypothesized that these LMWPs would also inherit the similar translocation activity across the cell membrane, which enables any impermeable species to be transduced into the cells. LMWPs were prepared by enzymatic digestion of protamine, examined their capability of transducing an impermeable protein toxin into the tumor cells by chemical conjugation, and determined cytotoxicity of transduced protein toxin (e.

Application of "ATTEMPTS" for drug delivery.

A novel enzyme drug delivery system, Antibody, Targeted, Triggered, Electrically, Modified, Prodrug, Type, Strategy ("ATTEMPTS"), was developed in our laboratory to attenuate the toxicity associated with drug activity at non-targeted tissues. Tissue plasminogen activator is a prime example of an enzyme drug that exhibits systemic toxicity due to its indiscriminate activation of both targeted (i.e.

[Experimental study on changes of sexual hormones in senior males living on high altitude].

Objectives: To investigate the characteristics of testosterone (T) and estradiol (E2) in senior males living on high altitude

Methods: According to the years of living on 3,100-meter high altitude. 90 senior males who were more than sixty years old were divided into three groups: group 1 (one year on the high altitude, n = 30), group 2 (two years on the high altitude, n = 30) and group 3 (over 10 years on the high altitude, n = 30). Additionally, there was a control group (living on the sea level).

Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study.

Background: The structural similarity between low molecular weight protamine (LMWP), prepared by enzymatic digestion of protamine, and HIV-TAT protein transduction peptide suggested the feasibility of LMWP as an efficient carrier for delivering therapeutic genes while alleviating the cytotoxicity of currently employed gene carriers.

Methods: LMWP was prepared by enzymatic digestion of protamine with thermolysine. The prepared LMWP peptide and TAT peptide, as well as their complexes with plasmid DNA (pDNA), were examined for cellular uptake behaviors by using confocal microscopy and flow cytometry.

ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects.

A prodrug type delivery system based on competitive ionic binding for the conversion of the prodrug to an active drug has been developed for delivery of enzyme drugs without their associated toxic side-effects. This approach, termed "ATTEMPTS" (antibody targeted, triggered, electrically modified prodrug-type strategy), would permit the administration of an inactive drug and then subsequently triggered release of the active drug at the target site. The underlying principle was to modify the enzyme with small cationic species so that it could bind a negatively charged heparin-linked antibody, and the latter would block the activity of the enzyme drug until it reached the target.